PRESS RELEASE:

Reaction Biology Launches Recombinant Methyltransferase Line

| From
drug discovery

MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ("RBC"), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC's initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.

The enzymes offered for sale are active and validated for use in high-throughput screening assays. In the case of the HMTs those assays employ RBC's proprietary HotSpot(SM) methodology, which couples economical screening with the data quality of a "gold standard" radiometric approach. HMTs are also routinely assayed by conventional scintillation counting in a plate format (TopCount).

"Our assay expertise is helping us make better enzymes, while the ability to produce new proteins in-house will help us expand the range of assays we can offer, and provide our clients with a more complete drug discovery process," said Konrad Howitz, RBC's Director of Epigenetics.

In addition to the HDAC, Sirtuin, HMT, DNMT and HAT assays currently offered, RBC has innovative assays for demethylases and epigenetic readers in active development.

Based in Malvern, PA, RBC has become a premier provider of drug screening and profiling services. With more than 400 kinases, RBC's coverage of the kinome is the broadest in the industry. Using its proprietary HotSpot(SM) technology and other innovations, RBC is expanding its already substantial coverage of epigenetic regulatory enzymes. RBC has provided its services to over 200 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.

For more information, visit: http://www.reactionbiology.com .

News Source:
MORE INFORMATION:
For more information regarding this press release, please visit:
http://www.reactionbiology.com
Like, Share, Save this press release:
  TWEET   SHARE   G+   PIN IT   STUMBLE   LinkedIn   Instapaper   Buffer

PERMALINK:
https://www.send2press.com/newswire/2011-10-1024-002.shtml
  LEGAL NOTICE AND TERMS OF USE:  
The content of the above press release was provided by the “news source” (Reaction Biology Corporation) or authorized agency, who is solely responsible for its accuracy. Send2Press® is the originating wire service for this story and content is Copr. © 2011 Reaction Biology Corporation with newswire version Copr. © 2011 Send2Press (a service of Neotrope). All trademarks acknowledged.

Rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
STORY READS for this single page only, as of Oct 01 2016:
[ count retired 8.4.16 ]


back to top
REFERENCES: drug discovery, HotSpot methodology, Konrad Howitz, HotSpot methodology, Reaction Biology Corporation, drug discovery services in epigenetics, RBC, pharmaceutical, biotech, drug screening and profiling services, histone methyltransferases, Pennsylvania, news, press release from Reaction Biology Corporation, Oct 24, 2011, Drugs and Pharmaceuticals, Medical, Product Launches, Malvern, Pennsylvania, Reaction Biology Launches Recombinant Methyltransferase Line